Mast Therapeutics, Inc.
https://savarapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mast Therapeutics, Inc.
EMA Recommends Stemline’s Elzonris After Initial Rejection
While the European Medicine Agency now recommends that Elzonris should be approved in the EU, Stemline Therapeutics will have to submit the results of a study based on a registry of patients with blastic plasmacytoid dendritic cell neoplasm.
Strides Begins Biosimilar Filings With Teriparatide
Strides files for a biosimilar to Eli Lilly’s Forteo (teriparatide) in the EU, marking the beginning of its journey in the biosimilars segment. Meanwhile, it hopes to enter a manufacturing tie-up with COVID-19 vaccine players in H2 while also planning a launch of favipiravir in markets outside India.
Strides Begins Biosimilar Filings With Teriparatide
Strides files for a biosimilar to Eli Lilly’s Forteo (teriparatide) in the EU, marking the beginning of its journey in the biosimilars segment. Meanwhile, it hopes to enter a manufacturing tie-up with COVID-19 vaccine players in H2 while also planning a launch of favipiravir in markets outside India.
Keeping Track Of Breakthroughs: AZ Farxiga, ImmunoGen ADC For Hematologic Cancer, Inventiva NASH Candidate Earn Designation
The latest breakthrough therapy designation news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
- Other Names / Subsidiaries
-
- Adventrx Pharmaceuticals, Inc.
- Aires Pharmaceuticals, Inc.
- SynthRx, Inc.